Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients with HER2-positive Advanced Gastro-Oesophageal Adenocarcinoma By Ogkologos - June 1, 2026 143 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HERIZON-GEA-01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR “Selfless and Incredible” Mother Leaves Behind Five Children After Battling Breast... November 25, 2020 Screening Programme by Primary Colonoscopy or Two Rounds of Two-Stool FIT... February 26, 2026 The Barriers to Care Faced by LGBTQ People With Cancer: An... January 21, 2021 Sacituzumab Govitecan Demonstrates Overall Survival Benefit Over Chemotherapy in Patients with... September 18, 2023 Load more HOT NEWS Snowboarder Wins Gold Medal At Winter Olympics After Beating Cancer Tattoo Artist Helps Breast Cancer Survivors Cover Their Port Scars Alex Trebek Has Completed Chemo And Will Be Back For The... COVID-19 Vaccines: Considerations for Special Populations
